Exosome therapy & extracellular vesicles

01Overview and value chain

Markers: [EC: Advanced Therapy Medicinal Products (ATMP) framework | OECD: Bio-pharmaceuticals | Regulator: FDA (US), EMA (EU), NMPA (China)]

Exosomes and other extracellular vesicles (EVs) are nanoscale membrane vesicles (roughly 30-150 nm) secreted by nearly all human cell types, naturally carrying lipids, proteins, mRNA and microRNA between cells as a form of intercellular communication. The field splits into two parallel tracks: native EVs purified from mesenchymal stem cells (MSCs) for their inherent anti-inflammatory and regenerative properties without the oncogenicity or embolism risk of live-cell therapy, and engineered EVs loaded with therapeutic cargo (siRNA, mRNA, proteins or CRISPR-Cas9 components) and surface-modified to target specific tissues. Evox Therapeutics (UK) has developed its DeliverEX platform specifically to engineer and load exosomes with RNA payloads and gene-editing tools including CRISPR-Cas9 for targeted delivery to difficult-to-reach tissue. Capricor Therapeutics is furthest along in the clinic among the companies here, though its lead asset, Deramiocel (formerly CAP-1002), is technically an allogeneic cardiosphere-derived cell therapy rather than an isolated exosome product — its anti-inflammatory benefit in Duchenne muscular dystrophy is believed to work partly through paracrine exosome secretion, and the company’s BLA is now scheduled for an FDA Advisory Committee review on July 29, 2026, backed by five-year HOPE-2 Open-Label Extension data and Phase 3 HOPE-3 trial results. Aegle Therapeutics is running a Phase 1/2a trial of AGLE-102, an MSC-derived extracellular-vesicle therapy, in patients with dystrophic epidermolysis bullosa, having dosed its first patient and reported positive initial safety data. Anjarium Biosciences (Switzerland) is developing hybrid vesicles that combine synthetic DNA constructs with vesicle-based delivery for cell and gene therapy applications. Underpinning the whole field, the International Society for Extracellular Vesicles (ISEV) maintains the MISEV guidelines (most recently updated as MISEV2023) that define the minimal characterization standards — nomenclature, purity verification, membrane-marker confirmation — that both EMA and FDA lean on when evaluating EV-based products.

The key directions of exosome therapy and extracellular vesicles are:

1. Native (unmodified) exosomes: purified vesicles from human mesenchymal stem cells, valued for the anti-inflammatory, immunomodulatory and regenerative properties of the parent cell without live-cell therapy risks.
2. Engineered (loaded) exosomes: vesicles used as biocompatible nanocontainers for targeted delivery of therapeutic cargo — siRNA, mRNA, therapeutic proteins or CRISPR-Cas9 systems — with surface-modified targeting ligands.
3. Hybrid vesicles: artificially assembled particles combining native-exosome biocompatibility with synthetic-nanoparticle cargo capacity, aiming to overcome the loading-capacity limits of pure exosomes.
4. Standardized characterization: internationally agreed criteria (ISEV’s MISEV guidelines) for confirming a preparation is genuinely composed of exosomes at defined purity, size and membrane-marker profile.

Sectoral value chain

[MSC/donor-cell culture] ──> [Supernatant harvest & TFF concentration] ──> [Ultracentrifugation / chromatography purification]
                │                                        │                                          │
       (Bioreactor, suspension)                 (Primary clarification)                    (Ultra-pure vesicles)
                                                                                                       │
[Finished GMP product] <──── [Fill/finish & potency assay] <─── [Cargo loading (electroporation/sonication)] <──┘

Value chain levels

Cross-cutting technologies of the sector:

• Nanoparticle tracking analysis (NTA): laser-illuminated video microscopy that tracks Brownian motion of individual vesicles and applies the Einstein-Stokes equation to calculate each particle’s hydrodynamic diameter and the batch’s precise particle concentration.
• Exosome electroporation: brief microsecond electrical pulses that transiently open pores in the vesicle’s lipid bilayer in the presence of a concentrated therapeutic cargo, allowing cargo to enter before the pores self-seal.
• Hollow-fiber bioreactor culture: donor cells grow in the extracapillary space of a bundle of porous hollow-fiber membranes, with perfused media supplying nutrients while secreted vesicles accumulate at very high concentration outside the fiber lumen, simplifying downstream purification.

02US

The United States hosts the most clinically advanced extracellular-vesicle programs among the companies covered, alongside a defined FDA regulatory pathway for the category.

Capricor’s Deramiocel nearing FDA review, Aegle’s epidermolysis bullosa trial, FDA biological-product classification

• Capricor Therapeutics: its lead asset Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell therapy whose benefit in Duchenne muscular dystrophy is believed to work partly through paracrine exosome secretion, has a Biologics License Application now scheduled for FDA Advisory Committee review on July 29, 2026, backed by five-year HOPE-2 Open-Label Extension data and Phase 3 HOPE-3 trial results.
• Aegle Therapeutics: is running a Phase 1/2a trial of AGLE-102, an MSC-derived extracellular-vesicle therapy for dystrophic epidermolysis bullosa, having dosed its first patient and reported positive initial safety data.
• FDA regulatory classification: the FDA classifies exosome-based products as biological products, requiring rigorous viral-safety testing of cellular raw material, particle-size stability confirmation and a validated potency assay for every batch.

03CN

China’s most significant 2026 development in this Industry is regulatory rather than corporate: the formal classification of extracellular vesicles as an advanced therapy category.

CDE’s ATMP classification of extracellular vesicles, MSC-exosome cosmetics market, regenerative-medicine demand

• Regulatory landmark: China’s Center for Drug Evaluation (CDE, under NMPA) issued a draft consultation document in June 2025 that for the first time formally classified extracellular vesicles as falling within the “advanced therapy medicinal products” (ATMP) regulatory category, alongside cell and gene therapies.
• MSC-exosome cosmetics and regenerative medicine: China has become a major consumer market for MSC-derived exosome serums and patches marketed for skin regeneration and anti-aging, alongside growing clinical interest in MSC-exosome therapy for conditions such as Parkinson’s disease and respiratory disease.
• Fragmented company landscape: while multiple Chinese biotech companies and stem-cell-bank operators are active in exosome R&D and commercial products (including at least one company marketing a branded exosome nebulizer product), no single company could be confirmed by name via a live 2026 source as a clear market leader comparable to the US/EU companies profiled here.

04EU

Europe hosts the leading standards body for the entire field alongside advanced engineered-exosome and hybrid-vesicle developers.

ISEV’s MISEV standards, Evox’s DeliverEX platform, Anjarium’s hybrid vesicles

• ISEV (International Society for Extracellular Vesicles): maintains the MISEV guidelines (most recently updated as MISEV2023), which set the field’s minimal characterization standards for confirming vesicle identity, purity and membrane-marker profile — standards both EMA and FDA reference when evaluating EV-based product submissions.
• Evox Therapeutics (UK): has developed its DeliverEX platform specifically to engineer and load exosomes with RNA payloads and gene-editing tools including CRISPR-Cas9 components for targeted delivery to difficult-to-reach tissue.
• Anjarium Biosciences (Switzerland): is developing hybrid vesicles that combine synthetic DNA constructs with vesicle-based delivery, presenting data on novel synthetic-DNA applications for cell and gene therapies at the American Society of Gene & Cell Therapy annual meeting.

05Leading companies and research institutes

06Tech stack and innovations

The extracellular-vesicle production and characterization stack pairs specialized bioreactor and purification hardware with precision analytical instrumentation to verify vesicle identity and purity:

1. Hollow-fiber bioreactor culture:
   • Donor cells (e.g. cord-derived MSCs or HEK293 cells) populate the extracapillary space of a dense bundle of porous hollow-fiber membranes; secreted vesicles cannot pass back through the small fiber pores and instead accumulate at very high concentration in the extracapillary space, sharply reducing the downstream concentration burden.
2. High-performance size-exclusion chromatography (SEC):
   • Concentrated vesicle preparations pass through porous polymer resin beads; larger exosomes elute first in the column’s free volume while smaller free proteins and DNA fragments are retained longer in the resin pores, achieving gentle separation without the pressure that could rupture fragile lipid membranes.
3. Nanoparticle tracking analysis (NTA):
   • A focused laser beam illuminates individual vesicles in a diluted sample, and software tracks each particle’s Brownian-motion trajectory frame by frame to calculate its diffusion coefficient and diameter, building a detailed particle-size-distribution profile for batch release.

07Value chains and production pipelines

Industrial pipeline for GMP manufacture and cryopreservation of human MSC-derived exosomes

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. 3D MSC culture in       │ ───> │ 2. Supernatant harvest &    │
│    hollow-fiber reactor        │      │    0.22 μm filtration          │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Chromatography           │ <─── │ 3. Tangential flow          │
│    (AEX/SEC) purification      │      │    concentration (TFF)         │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Trehalose addition &    │ ───> │ 6. Sterile filtration &     │
│    NTA marker verification    │      │    -80°C cryopreservation     │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: 3D MSC culture in hollow-fiber reactor

A Master Cell Bank vial of human umbilical-cord MSCs is thawed and expanded in standard T-flasks in a clean GMP zone; once a target cell number is reached, the suspension seeds the extracapillary space of a sterile hollow-fiber bioreactor cartridge, continuously perfused with serum-free, chemically defined medium (avoiding fetal bovine serum, which carries its own contaminating bovine exosomes) for roughly three weeks at 37°C and 5% CO2.

Stage 2: Supernatant harvest and 0.22 μm filtration

The vesicle-rich extracapillary fluid is harvested and passed through a 0.22 μm filter to remove any cellular debris or contaminating microorganisms before downstream concentration.

Stage 3: Tangential flow concentration (TFF)

The clarified supernatant is concentrated and diafiltered by tangential flow filtration with a 100 kDa cutoff membrane, reducing volume while retaining the vesicle fraction and removing small-molecule contaminants.

Stage 4: Chromatography (AEX/SEC) purification

The concentrate passes through anion-exchange or size-exclusion chromatography media to remove residual free proteins and DNA, yielding a purified native exosome fraction in the 30-150 nm size range.

Stage 5: Trehalose addition and NTA marker verification

A cryoprotectant (typically trehalose) is added to stabilize the vesicle membranes for freezing, and nanoparticle tracking analysis confirms particle concentration and size distribution alongside flow-cytometry verification of CD9/CD63/CD81 membrane markers.

Stage 6: Sterile filtration and -80°C cryopreservation

The final formulated product undergoes sterile filtration, is filled into single-use vials, and is cryopreserved at -80°C, with a certificate of analysis accompanying each batch for GMP release.